September 10, 2025Journal of Thoracic DiseaseOpen Access

Improvement of survival outcomes in patients with advanced-stage non-small-cell lung cancer treated with chemotherapy: a retrospective cohort study evaluating the role of immune checkpoint inhibitors

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective cohort study shows improved overall survival with immune checkpoint inhibitors in patients, indicating effective treatment strategies.

Median overall survival improved from 11.5 months to 20.7 months with the use of immune checkpoint inhibitors in advanced lung cancer patients.
The use of immune checkpoint inhibitors increased significantly over three study periods, from 0% in the first period to 79.4% in the last.
Cox regression analysis showed immune checkpoint inhibitors significantly associated with improved overall survival, with a hazard ratio of 0.52.
The findings underscore the importance of integrating immune checkpoint inhibitor therapies into treatment plans for patients without actionable mutations.

Sakamori et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort study shows improved overall survival with immune checkpoint inhibitors in patients, indicating effective treatment strategies.